Table 2.
Multivariable analysis to assess for independent cardiovascular risk factors associated with the development of a cardiovascular event
| Predictor | Odds ratio | p-value | 95% Confidence Interval |
|---|---|---|---|
| Sex (M - F) | 2.85 | 0.014 | 1.25–6.63 |
| Age at nilotinib commencement | 1.05 | < 0.001 | 1.02–1.09 |
|
ECOG: 1 − 0 2 − 0 |
4.7 1.19 |
0.067 0.91 |
0.89–24.8 0.05–23.9 |
| Total months on Nilotinib | 1.00 | 0.26 | 0.99–1.02 |
| Nilotinib starting dose | 0.46 | 1.00 | 0.99–1.00 |
| Smoker (yes – no): | 1.18 | 0.71 | 0.48–2.92 |
| Dyslipidaemia (yes – no): | 2.17 | 0.061 | 0.11–4.94 |
|
Obesity [BMI > 30] (yes-no): |
0.57 | 0.27 | 0.21–1.54 |
| Known ischaemic heart disease (yes – no): | 0.49 | 0.35 | 0.11–2.12 |
| Hypertension (yes – no) | 0.76 | 0.62 | 0.25–2.26 |
| Chronic kidney disease (yes – no) | 6.5 | 0.057 | 0.52–33.4 |
| Arrhythmia (yes – no) | 4.20 | 0.18 | 0.44–13.93 |
M = male, F = female, BMI = body mass index